Literature DB >> 18178498

Idiopathic short stature: management and growth hormone treatment.

J M Wit1, E O Reiter, J L Ross, P H Saenger, M O Savage, A D Rogol, P Cohen.   

Abstract

In the management of ISS auxological, biochemical, psychosocial and ethical elements have to be considered. In boys with constitutional delay of growth and puberty androgens are effective in increasing height and sexual characteristics, but adult height is unchanged. GH therapy is efficacious in increasing height velocity and adult height, but the inter-individual variation is considerable. The effect on psychosocial status is uncertain. Factors affecting final height gain include GH dose, height deficit in comparison to midparental height, age and first year height velocity. In case of a low predicted adult height at the onset of puberty, addition of a GnRH analogue can be considered. Although GH therapy appears safe, long-term monitoring is recommended.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18178498     DOI: 10.1016/j.ghir.2007.11.003

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  15 in total

1.  Should idiopathic short stature be treated with growth hormone?

Authors:  Martin O Savage
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2009-03

Review 2.  Nonclassical GH Insensitivity: Characterization of Mild Abnormalities of GH Action.

Authors:  Helen L Storr; Sumana Chatterjee; Louise A Metherell; Corinne Foley; Ron G Rosenfeld; Philippe F Backeljauw; Andrew Dauber; Martin O Savage; Vivian Hwa
Journal:  Endocr Rev       Date:  2019-04-01       Impact factor: 19.871

3.  Common VDR polymorphisms and idiopathic short stature in children from northern Greece.

Authors:  E Emmanouilidou; A Galli-Tsinopoulou; I Kyrgios; E Gbandi; A Goulas
Journal:  Hippokratia       Date:  2015 Jan-Mar       Impact factor: 0.471

4.  First-year predictors of health-related quality of life changes in short-statured children treated with human growth hormone.

Authors:  J Quitmann; J Bloemeke; H-G Dörr; M Bullinger; S Witt; N Silva
Journal:  J Endocrinol Invest       Date:  2019-03-06       Impact factor: 4.256

5.  The Effect of Gonadotropin-Releasing Hormone Analogue on Final Adult Height in Children with Idiopathic Short Stature.

Authors:  Nahla Khawaja; Hala Owaineh; Anwar Batieha; Oraib Frahid; Mohammed El-Khateeb; Kamel M Ajlouni
Journal:  Med Princ Pract       Date:  2019-04-16       Impact factor: 1.927

6.  The psychometric evaluation of the quality of life in short stature youth (QoLISSY) instrument for German children born small for gestational age.

Authors:  R Sommer; J Blömeke; M Bullinger; J Quitmann
Journal:  J Endocrinol Invest       Date:  2018-02-17       Impact factor: 4.256

Review 7.  Treatment of children and adolescents with idiopathic short stature.

Authors:  Michael B Ranke
Journal:  Nat Rev Endocrinol       Date:  2013-04-23       Impact factor: 43.330

8.  Genetic evidence that thyroid hormone is indispensable for prepubertal insulin-like growth factor-I expression and bone acquisition in mice.

Authors:  Weirong Xing; Kristen E Govoni; Leah Rae Donahue; Chandrasekhar Kesavan; Jon Wergedal; Carlin Long; J H Duncan Bassett; Apostolos Gogakos; Anna Wojcicka; Graham R Williams; Subburaman Mohan
Journal:  J Bone Miner Res       Date:  2012-05       Impact factor: 6.741

9.  Efficacy of short-term growth hormone treatment in prepubertal children with idiopathic short stature.

Authors:  Ho-Seong Kim; Sei Won Yang; Han-Wook Yoo; Byung Kyu Suh; Cheol Woo Ko; Woo Yeong Chung; Kee Hyoung Lee; Jin Soon Hwang; Hyi-Jeong Ji; Hyunji Ahn; Duk Hee Kim
Journal:  Yonsei Med J       Date:  2014-01       Impact factor: 2.759

10.  Towards identification of molecular mechanisms of short stature.

Authors:  Lindsey A Waldman; Dennis J Chia
Journal:  Int J Pediatr Endocrinol       Date:  2013-11-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.